Barbara Rubel, Compassion Fatigue Speaker’s Post

Did you miss Avance Clinical's live Psychedelics In Focus webinar on Monday? The webinar featured a fascinating conversation between Senior Director of Scientific and Regulatory Services, Jorgen Mould and Senior Vice President Scientific and Regulatory Affairs Kevin Leach, Ph.D, DABT. Delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder. Simply register via the Xtalks website 👇 https://lnkd.in/eywUiP3i #AvanceClinical #CRO #psychedelicscience #psychedelicresearch #clinicalresearch #newmedicines #depression #anxiety #webinar

Click on the following link to read the article: Clinical insights for major depressive disorder https://hubs.la/Q02G1p650. This overview of MDD includes clinical presentation, pathophysiology, diagnosis and treatment: 1. Case Vignette: Illustrates common challenges in MDD management, like medication timelines and therapy adjustments 2. Detailed Pharmacotherapy Discussion: SSRIs, SNRIs and other antidepressant classes plus adjunctive therapies like CBT 3. Guidance for Improved Treatment Outcomes: The importance of a multidisciplinary approach and regular monitoring 4. Recognising the Risks: Ongoing management and preventive strategies Mark Mental Illness Awareness Month this July by understanding more about MDD – a chronic, recurrent condition with significant morbidity.

Eye-opening read on the effects of all sorts of trauma on the human body. As I am half way through my MSK outpatients rotation, this book has helped immensely my understanding on the injuries and insults we experience, and how they may present physically, physiologically or behaviorally. While it is outside my scope of practice to perform the myriad of ground-breaking techniques suggested in the book like EMDR (eye movement densitization and reprocessing), IFS (internal family systems therapy); it provided useful insight on physiological and neuro-anatomical imbalances in the post-traumatic population; and the detriments of relying on pharmacological interventions for PTSD. For example, traumatized people (much of which encompass the persistent pain population) have unusually low heart rate variability, meaning disparities in sympathetic and parasympathetic nervous system function, explaining why these people are vulnerable to over-respond to minor stressors. This has helped with how I approach patients with persistent pain - the education of pain, trauma and addressing not only their physical symptoms, but systemic; and helping patients highlight areas of their lives that may be restricting their change and addressing the stages of change model. #physiotherapy #painmanagement #nhs

Recently, the FDA has accepted a supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline to treat adults with post-traumatic stress disorder (PTSD). This combination therapy, supported by data from three randomized clinical trials, demonstrated consistent reductions in #PTSD symptoms. If approved, it would be the first FDA-approved pharmacological option for PTSD in over 20 years. PTSD is a prevalent mental health disorder, affecting approximately 13 million adults annually in the US. Read the complete article here: https://lnkd.in/gqDN3yKa Follow Actu-Real for more insightful posts on #healthcare, AI, machine learning, health economics, outcomes research, and real-world data. #ActuReal #Trending #Healthcare #FDA #PTSDTreatment

Do you suffer from Depression? tVNS® led to a reduction of depression-specific HAMD score of minimum 2-3 points in adult patients when used in parallel with psychopharmacological and psychotherapy treatments after a period of 9 weeks. Thousands of patients have put their trust in tVNS® and have found great results in managing their neurological conditions. With its non-invasive approach, patient-centered therapies, and minimal adverse effects, tVNS® presents a fresh perspective of hope and comfort for individuals who are struggling to manage their Depression. If you are currently struggling with Depression or know someone who is, please explore our website for more details & success stories on how our tVNS® device can help manage symptoms of Depression. tVNS® is certified as a Class lla medical device under the European Medical Device Regulation (MDR), and offers trusted and safe therapy for managing neurological, mental and physical health conditions. #depression #depressionsymptoms #livingwithdepression #depressionsymptoms #tvns

💚 Personality Disorders are common and often developed in response to trauma and lifetime events in early years. The are developed patterns of thinking, meaning making and behaving that are difficult to break and require huge bravery to face and acknowledge. 💚 When working in healthcare, we should take care not to add to the stigma by not understanding this diagnosis and humanising the experience of the person we are working with. 💚 We may need to adapt and re-formulate how we form and maintain the therapeutic relationship and be wary of how the person's PD may interact with the relationship. We can support people with pain AND personality disorder(s) but only through knowledge, understanding and compassion. For more information on PD and pain-specialised physiotherapy (or other non-psycholgy trained work) why not sign up to The Clinical Coaching Pod this year! Linkinbio #mentalhealthmatters #physiotherapy #paintherapy #personalitydisorder #chronicpain

Randomized clinical trials have demonstrated that IV ketamine infusion can rapidly improve depressive symptoms, including suicidal ideation. In many cases, its effects can be felt within a 30-40 minute period after the first infusion. And unlike more traditional psychiatric medications which can take 6-8 weeks to work, people often feel a difference after one or two sessions. IV ketamine therapy has been shown to relieve the symptoms of depression in 70-80% of cases. 🌅 Golden Afternoon - Get a free consultation for us to get to know you better at https://buff.ly/3wnpRLI #GoldenAfternoon #Ketamine #Clinic #Therapy #LosAngeles #California #MentalHealth #Neuroplasticity #Infusions #Antidepressants #Anxiety #MoodDisorders #PTSD #ChronicPain

At Perth Clinic, our commitment has always been toward evidence-based, innovative approaches that make a real difference in mental health care. It's therefore exciting to revisit the study recently published in Nature Medicine. This Phase 3 clinical trial dives into the potential of MDMA-assisted therapy for treating moderate to severe PTSD. The trial has been recognised for its robust methodology—multi-site, randomised, and double-blind—as well as its diverse participant pool. These design choices not only bolster the study's findings but also address a glaring gap in mental health research by including underrepresented groups disproportionately affected by PTSD. The outcomes are worth considering: significant reductions in both PTSD symptom severity and functional impairment were observed. However, the study also shows a balanced view by noting some severe treatment-emergent adverse events. In essence, while we are stepping closer to potentially transformative therapies for PTSD, the findings remind us to proceed with both scientific rigour and ethical responsibility. We invite our colleagues and partners to delve into this study, and maintain a discerning perspective about the reality of integrating these treatments into mainstream mental health services. Let's continue the discussion that leads to improved mental health solutions, always backed by solid evidence and compassionate care. Best Regards, The Team at Perth Clinic Reference: Mitchell, J. M., Ot’alora G., M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., ... & MAPP2 Study Collaborator Group. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29, 2473–2480. #PTSD #MDMA #MentalHealth #ClinicalTrials #Innovation #NatureMedicine #EvidenceBased #PerthClinic

What is TMS used for? 🔎 In Australia, TMS is currently TGA-approved for the treatment of depression, with Medicare rebates now available for eligible* adult patients that have tried two or more antidepressant medications without any significant benefits to their symptoms. It is generally used for those patients who do not see improvements from other treatments. TMS may also help patients with other conditions, such as OCD, PTSD, pain management and tinnitus, with evidence continuing to emerge for a range of psychiatric and neurological conditions. 👉 For more information on TMS and how it works, visit our website at www.modalis.com.au or email our friendly team at tms@modalis.com.au. #tms #tmstherapy #tmsaustralia #rtms #transcranialmagneticstimulation #repetitivetranscranialmagneticstimulation #brainstimulation #neuroscienceaustralia #perthclinic #perth

Schizoaffective Disorder presents complex challenges, but innovative treatments offer renewed hope for managing its symptoms effectively. Integrative approaches combining antipsychotic medications with cognitive-behavioral therapy (CBT) address both psychotic and mood symptoms. Emerging techniques like Electroconvulsive Therapy (ECT) demonstrate efficacy, particularly in severe cases resistant to conventional treatments. Additionally, transcranial direct current stimulation (tDCS) shows promise in regulating mood and cognition. Personalized treatment plans that incorporate these innovative methods offer improved outcomes, enhancing the quality of life for individuals grappling with Schizoaffective Disorder. #StatenIslandNY #SchizoaffectiveDisorder #PsychiatricServices #InnovativeSchizoaffectiveCare #PersonalizedTreatment